MRVI Jan 2025 12.500 call
| Previous close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.1500 |
| Ask | 0.8000 |
| Strike | 12.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.2000 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 71 |
Insider MonkeyHere’s Why RGAIA Considers Maravai LifeSciences Holdings’ (MRVI) Margin Structure as the Best
RGA Investment Advisors, an investment management company released its first quarter 2024 investor letter. A copy of the letter can be downloaded here. Strong economic growth combined with frustratingly resilient inflation defined the macroeconomic environment in the first quarter. The large caps outperformed their smaller counterparts in Q1. It may be the result of continued […]
GuruFocus.comSteven Cohen's Strategic Acquisition in Maravai LifeSciences Holdings Inc
On June 7, 2024, Steven Cohen (Trades, Portfolio)'s firm made a significant addition to its investment portfolio by acquiring 6,647,015 shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI). This move has increased the firm's stake in Maravai LifeSciences to 5.00% of the total shares outstanding, reflecting a strategic position with a 0.14% portfolio weight and a trade impact of 0.11%. Steven A. Cohen, Chairman and CEO of Point72, a prominent investment advisor, has a distinguished career in the financial markets.
ZacksMaravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
